217 related articles for article (PubMed ID: 35190477)
1. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
[TBL] [Abstract][Full Text] [Related]
2. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B; López-Arrieta J; Lipschitz S; Doskas T; Spiru L; Moroz S; Venger O; Vermersch P; Moussy A; Mansfield CD; Hermine O; Tsolaki M;
Alzheimers Res Ther; 2023 Feb; 15(1):39. PubMed ID: 36849969
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
4. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
Mora JS; Genge A; Chio A; Estol CJ; Chaverri D; Hernández M; Marín S; Mascias J; Rodriguez GE; Povedano M; Paipa A; Dominguez R; Gamez J; Salvado M; Lunetta C; Ballario C; Riva N; Mandrioli J; Moussy A; Kinet JP; Auclair C; Dubreuil P; Arnold V; Mansfield CD; Hermine O;
Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):5-14. PubMed ID: 31280619
[No Abstract] [Full Text] [Related]
5. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Deplanque G; Demarchi M; Hebbar M; Flynn P; Melichar B; Atkins J; Nowara E; Moyé L; Piquemal D; Ritter D; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Hammel P
Ann Oncol; 2015 Jun; 26(6):1194-1200. PubMed ID: 25858497
[TBL] [Abstract][Full Text] [Related]
7. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Vermersch P; Benrabah R; Schmidt N; Zéphir H; Clavelou P; Vongsouthi C; Dubreuil P; Moussy A; Hermine O
BMC Neurol; 2012 Jun; 12():36. PubMed ID: 22691628
[TBL] [Abstract][Full Text] [Related]
8. Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials.
Hamad AA; Amer BE
Neurol Sci; 2024 Jul; 45(7):3503-3507. PubMed ID: 38627298
[TBL] [Abstract][Full Text] [Related]
9. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
10. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
11. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
12. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
[TBL] [Abstract][Full Text] [Related]
18. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X; Arnold DL; Weber MS; Staikov I; Piasecka-Stryczynska K; Willmer J; Martin EC; Dangond F; Syed S; Wolinsky JS;
N Engl J Med; 2019 Jun; 380(25):2406-2417. PubMed ID: 31075187
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
20. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]